Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

"AL3818: Part 1 - 12 mg, 10 mg, 8 mg, or 6 mg (by dosing cohort), Part 2 - RP2D (as determined from Part 1).~Administered orally once daily on Days 1-14 per 21 day Cycle."

Nivolumab 240 mg Administered by injection every 2 weeks (Odd Cycles: Days 1 and 15 and Even Cycles Day 8) per 21 day Cycle.